Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amsterdam PrEP demonstration project in MSM
NL-OMON42253Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Acceptability of PrEP, Feasibility of PrEP and 1 more. Started Aug 2015; status: active, not recruiting.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON42253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42253.